Roles of tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, platelet-activating factor, and arachidonic acid metabolites in interleukin-1-induced resistance to infection in neutropenic mice by Vogels, M.T.E. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
This full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/14897
 
 
 
Please be advised that this information was generated on 2014-11-11 and may be subject to
change.
I n f e c t io n  a n d  I m m u n it y , May 1994, p. 2065-2070 
0019-9567/94/$04.00+0
Copyright © 1994, American Society for Microbiology
Vol. 62, No. 5
Roles of Tumor Necrosis Factor Alpha, Granulocyte- 
Macrophage Colony-Stimulating Factor, Platelet-Activating 
Factor, and Arachidonic Acid Metabolites in Interleukin-1- 
Induced Resistance to Infection in Neutropenic Mice
M A R IA  T. E. V O G E L S , 1 C. C. H E R M S E N ,2 H. L. P. G. H U Y S ,3 W Y N A N D  M. C. E L IN G ,2
AND JO S W. M. VAN DER M E E R 1*
Department o f  Medicine,' Department o f  Medical Microbiology’,2 and Department o f  Hematology,3,
University Hospital, Nijmegen, The Netherlands
Received 18 October 1993/Returned for modification 10 December 1993/Accepted 28 February 1994
Treatment with a single low dose (80 to 800 ng) of interleukin-1 (IL-1) 24 h before a lethal bacterial challenge 
in granulocytopenic and in normal mice enhances nonspecific resistance. The mechanism behind this 
protection has only partially been elucidated. Since IL-1 induces production of tumor necrosis factor alpha 
(TNF-a), granulocyte-macrophage colony-stimulating factor (GM-CSF), platelet-activating factor (PAF), and 
arachidonic acid metabolites, we investigated the potential role of these substances in IL-l-induced protection. 
Low doses of murine TN F-a but not of human TNF-a enhanced survival, suggesting an effect via the type II 
TNF receptor rather than the type I TNF receptor, which has little species specificity. In line with this 
TNF-a-induced protection from infection, pretreatment with a low dose of a rat anti-murine TNF-a  
monoclonal antibody tended to inhibit IL-l-induced protection, suggesting a role o f  T N F -a  as a mediator of 
IL-l-induced enhanced resistance to infection. Pretreatment with higher doses of anti-TNF-a, however, showed 
a dose-related protective effect per se, which could be further enhanced by a suboptimal dose of IL-1. A 
combination of optimal doses of anti-TNF-a and IL-1 produced an increase in survival similar to that 
produced by separate pretreatments. This lack of further enhancement of survival by combined optimal 
pretreatments suggests a similar mechanism of protection, most likely attenuation of deleterious effects of 
overproduced proinfiammatory cytokines like TNF-a during lethal infection. Pretreatment with different doses 
of GM-CSF before a lethal Pseudomonas aeruginosa challenge in neutropenic mice did not enhance survival. 
Different doses of WEB 2170, a selective PAF receptor antagonist, of MK-886, a selective inhibitor of 
leukotriene biosynthesis, or of several cyclooxygenase inhibitors did not reduce the protective effect of IL-1 
pretreatment. We conclude that IL-l-induced nonspecific resistance is partially mediated by induction of  
TN F-a and not by GM-CSF, PAF, and arachidonic acid metabolites. The mechanism of action of IL-1 seems 
to be similar to that of anti-TNF-a.
Interleukin-1 (IL-1), two 17-kDa proteins (IL-1 a  and IL -Iß )  
produced by many different types of cells, possesses a wide 
spectrum  of biological p roperties  (6 ). In animals, adm inistra­
tion of IL-1 has been shown to enhance  nonspecific resistance 
to gram-positive and gram-negative bacteria, fungi, and plas­
modia (41). For instance, trea tm en t of both neutropenic  and 
normal mice with a single low dose (3 to 30 |JLg/kg of body 
weight) of recom binant hum an IL - lß  ( rh IL - lß )  24 h before a 
lethal infection with gram-negative bacteria  enhances survival 
(36, 37). The exact mechanism of this protective effect is still 
unclear. A direct antimicrobial effect of IL-1 has been excluded 
in vitro (37). W hether  IL-1 enhances the clearance of m icro­
organisms in vivo is controversial (18, 22, 37); a lack of IL-1 
effect on bacterial counts argues against this mechanism in our 
infection m odel (36). The protective effect of IL-1 against 
infectious challenges in granulocytopenic mice indicates that 
neutrophils do not play a m ajor role (18, 37, 41). Also, 
glucocorticosteroids and cytokines like IL-6 and IL-8 do not 
m ediate  IL -l- induced  enhanced  resistance (36-41). Recently,
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we showed that the protective effect of IL-1 in normal as well 
as in neu tropenic  mice is m ediated  to some extent by hepatic 
acute-phase proteins (38).
In the present study, the m echanism s of IL -l-induced  non- 
specific resistance have been further investigated, with special 
a tten tion  to o th e r  inflammatory m ediators induced by IL-1.
IL-1 generates production  of tum or necrosis factor alpha 
(T N F -a ) and granulocyte-m acrophage colony-stimulating fac­
tor (G M -C SF) in vitro as well as in vivo (26, 29). T N F -a  
possesses several potentially protective effects on the host 
resistance to pathogens, many of which are shared with IL-1 (4, 
34, 41). G M -C SF has, in addition to its effects on hem atopoi- 
esis, potent stimulating effects on m acrophage and neutrophil 
functions, and it induces several inflammatory m ediators (43). 
An in vivo role in antimicrobial host resistance has been shown 
for both  T N F -a  and G M -C SF (31, 32, 41).
In addition to these cytokines, IL-1 adm inistration induces 
production of eicosanoids like platelet-activating factor (PA F) 
(2 ) and arachidonic acid (8 ), the latter resulting in production 
o f  a variety of lipoxygenase and cyclooxygenase metabolites. 
Several effects o f  these m ediators  might be beneficial to the 
host in the enhancem en t of nonspecific resistance to infection
(2, 8 , 13, 41).
In this study, we have investigated the role of T N F -a ,  
G M -CSF, PAF, lipoxygenase, and cyclooxygenase products in
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IL -l-induced  enhanced resistance of neutropenic  mice to 
lethal gram-negative infection.
(Part of this paper  was presented  at the 4th In ternational 
T N F  Congress, 2 to 6 May 1992, Veldhoven, The N e th e r­
lands.)
MATERIALS AND METHODS
Mice. Fem ale outbred  Swiss mice (20 to 25 g; T N O , Rijswijk, 
The N etherlands) were kept under specific-pathogen-free con­
ditions. S tandard irradiated lab chow and acidified w ater were 
available ad libitum. To render mice neutropenic (< 0 .5  X 10y 
granulocytes per liter), two subcutaneous injections of cyclo­
phospham ide were adm inistered (150 and 100 mg/kg) on day 
— 4 and on day — 1, respectively, before infectious challenge 
(39).
Materials. Recom binant hum an IL-1 ß ( rh IL - lß )  was kindly 
provided by P. G raber  (Glaxo, Geneva, Switzerland) and P. 
G hiara  (Sciavo, Siena, Italy). According to the specifications of 
the suppliers, endotoxin contam ination in the Lim ulus  amoe- 
bocyte lysate assay was negligible (<1 .53  and <1.2  ng/mg, 
respectively). H um an and murine rT N F -a  were generously 
donated  by G. Adolf, Ernst-Boehringer Institut, Vienna, A us­
tria. Specific activities were 6 X 107 and 1.2 X 107 U/mg in 
murine LM cells, and endotoxin contents were <100 and <51 
pg/mg, respectively. M urine rG M -C SF (rm G M -CSF; a kind 
gift of I. Lindley, Sandoz, Vienna, Austria) had a specific 
activity of 6 X 107 U/mg in the murine bone marrow cell 
proliferation assay, and endotoxin content was 23 pg/mg. 
Cytokines were stored undiluted at - 7 0 ° C  and were diluted 
immediately before use in pyrogen-free isotonic phosphate- 
buffered saline (pH  7.4). Inactivated IL-1 was prepared  by 
heating IL-1 at 95°C for 30 min. To all these solutions, normal 
mouse serum was added to an end concentration of 2 % 
(vol/vol). W EB 2170, a specific competitive PA F receptor 
antagonist (14), was donated  by F. Pistel, Boehringer In­
gelheim, Ingelheim, Federal Republic of Germany. M K-886 , a 
5-lipoxygenase translocation inhibitor (12), was provided by J. 
W. Gillard, Merck Frosst C anada Inc., Quebec, Canada. W EB  
2170 and M K -886 were dissolved in 0.5% Tylose solution, 
freshly prepared  by dissolving carboxymethyl cellulose (Tylose; 
Hoechst, Frankfurt, Federal Republic of G erm any) in pyro­
gen-free distilled water. Indom ethacin  (Holland Pharm aceuti­
cal Supply, A lphen aan de Rijn, The N etherlands), acetylsali- 
cylic acid (G enpharm a, Maarssen, The N etherlands) and 
ibuprofen (Boots Pharmaceuticals, Nottingham , U nited  King­
dom ) were dissolved in pyrogen-free saline. Gentam icin was 
purchased from Schering, Kenilworth, N.J. Cyclophosphamide 
(A STA  Pharm a, Frankfurt, Federal Republic of G erm any) was 
dissolved in sterile pyrogen-free distilled water. Rat im m uno­
globulin G (IgG), containing 35 pg of endotoxin per mg, and 
lipopolysaccharide (LPS, from Escherichia coli serotype 0 5 5 :  
B5) were from Sigma Chemical Co., St. Louis, Mo.
The hybridoma producing the neutralizing rat anti-murine 
T N F -a  monoclonal antibody (M A b) V Iq  (7) was kindly p ro ­
vided by P. Kram m er, G erm an  C ancer Research Center, 
Heidelberg, Federal Republic of Germany. The rat MAb 
IgG2a(K) was purified from ascites by 45% am m onium  sulfate 
precipitation followed by dialysis against pyrogen-free distilled 
water, protein G chrom atography, and ano ther  dialysis step. 
LPS content (Lim ulus  amoebocyte lysate assay) was less than
8.2 pg/mg of protein. In the L929 bioassay (1), the rm T N F -a- 
neutralizing activity was 175 U/fxg. Bacteria for infectious 
challenges (Pseuclomonas aeruginosa A T C C  27853) were cul­
tured overnight and washed three times in saline, and ap p ro ­
priate dilutions were prepared .
L929 TNF bioassay. The L929 T N F  assay was perform ed as 
previously described (1). Briefly, 100,000 L929 cells were 
added  to serial twofold dilutions of rm TNF. The test was 
perform ed in the presence of 4 jjug of em etine (Sigma G m bH , 
Munich, Federal Republic of G erm any) per ml. A fter 20 h at 
37°C and 5%  C 0 2 in air at 90% relative humidity, TN F- 
m ediated cytopathic effects on L929 cells were evaluated with 
crystal violet at 540 nm (Sigma Chemical Co.). The detection 
limit of the assay was 80 pg/ml.
Experimental protocols. For survival experiments, IL-1, 
rm G M -C SF, rhT N F-a , rm T N F-« , or control trea tm ent (heat- 
inactivated IL-1) was adm inistered intraperitoneally (i.p.) (0.1 
ml) to neutropenic  mice 24 h before a lethal in tram uscular 
(i.m.) challenge with P. aeruginosa at time zero. To obtain 
reproducible survival curves, a relatively high bacterial chal­
lenge was given. This was com bined with gentamicin (120 
mg/kg) given subcutaneously 6 h after the bacterial challenge 
in o rder  to postpone the time of death  and thus accentuate  the 
differences between trea tm en t groups. Mortality was recorded 
for a period of at least 48 h after challenge. For investigations 
of the respective roles of T N F -a ,  PAF, and arachidonic acid 
metabolites in IL-l-induced  enhanced survival, V lq ,  a neu tra l­
izing anti-m urine T N F -a  MAb, was given intravenously (i.v.) 3 
h before the i.p. IL-1 injection, and W EB 2170 and M K -886 
were adm inistered orally by gavage 1 h before  the IL-1 in­
jection. The cyclooxygenase inhibitors ibuprofen, acetylsali- 
cylic acid, and indom ethacin were adm inistered orally (gavage) 
or intraperitoneally 45 min before the IL-1 injection.
In experim ents for confirming the in vivo activity of the 
an ti-T N F-a  MAb, serum T N F  bioactivity at 2 h after i.p. LPS 
was m easured in mice p re trea ted  i.v. with an ti-T N F-a  or saline
3 h before the LPS challenge. In addition, survival rates were 
com pared  in groups of mice p re trea ted  i.v. with an ti-T N F -a  or 
the same am ount of rat IgG 3 h before a lethal i.p. LPS 
challenge.
Statistical analysis. Survival data  were analyzed with the log 
rank test (28). P values of less than 0.05 were considered 
significant.
RESULTS
Effect of TNF-a- compared with IL-l-induced protection 
from infection. W e first investigated the role of T N F -a  in 
IL -l- induced  protection from infection. Different doses of 
hT N F-a , m T N F -a , or h IL - lß  were adm inistered i.p. to n eu ­
tropenic mice 24 h before a lethal i.m. P. aeruginosa challenge. 
As shown in Fig. 1A and B, both 80 and 800 ng of rhIL-1 ß 
produced significant protection in comparison with results with 
control mice. Survival rates were not significantly enhanced  by 
80 or 800 ng of rh T N F -a  and 80 ng of rm T N F-a . However, 800 
ng of rm T N F -a  enhanced survival rates significantly; this 
protection was not significantly different from protection in­
duced by 80 ng of rh IL - lß  (Fig. IB).
Effects of anti-TNF-a IgG. To investigate the role of T N F -a  
in IL -l- induced  protection from infection further, we assessed 
the effect of V lq ,  a neutralizing rat anti-m urine T N F -a  MAb. 
In experim ents by E ch tenacher et al. (7) and in ou r own 
experiments, intravenous p re trea tm en t with 5 X 104 neu tra l­
izing units of an ti-T N F-a  completely neutralized LPS-induced 
serum T N F -a  bioactivity. In addition, the same dose of anti- 
T N F -a  i.v. gave significant protection against a lethal i.p. LPS 
challenge (2.5 mg per mouse) adm inistered 3 h later (anti- 
T N F -a -p re trea ted  mice versus IgG -pre trea ted  mice; P <
0.025; 10 mice per group; data  not shown).
Adm inistration of an ti-T N F-a  (15, 60, or 400 jig per mouse
1.v.) 27 h before a lethal P. aeniginosa challenge enhanced
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FIG. 1. (A) Survival of neutropenic mice pretreated i.p. with 
different doses of rhIL-lß or rhTNF-a 24 h before a lethal i.m. P. 
aeruginosa challenge. Significantly greater protection in comparison 
with control mice (receiving heat-inactivated IL-lß) occurs in the 
groups pretreated with 80 or 800 ng of IL-lß (x2 = 7.74 and 10.01 and 
P < 0.01 and P < 0.05, respectively; 29 and 31 mice per group). (B) 
Survival of neutropenic mice pretreated i.p. with different doses of 
rhIL-lß or rmTNF-a 24 h before a lethal i.m. P. aeruginosa challenge. 
Significantly greater protection in comparison with control mice 
(receiving heat-inactivated IL-lß) occurs in the groups pretreated with 
80 or 800 ng of IL-lß (x2 as in panel B) and with 800 ng of rmTNF-a 
(X2 =  4.81 and P < 0.05; 30 mice per group). Horizontal axes, time 
(hours) postchallenge.
survival in a dose-dependen t fashion (in com parison with the 
same am ount of IgG: not significant, P  <  0.05, and P < 0.005, 
respectively; at least 1 1  mice per group; data  not shown). 
Survival after adm inistration of 400 |xg of an ti-T N F -a  at 27 h 
before the infectious challenge did not differ significantly from 
the survival after the same dose of an ti-T N F -a  given at - 3  h, 
and an ti-T N F -a  adm inistered at - 2 7  h gave protection to 
almost the same extent as the same dose adm inistered  at — 3 h 
(both com pared  with the same dose of IgG simultaneously: P 
=  0.08 and P < 0.05, respectively; 30 or 31 mice per group; 
data  not shown). T rea tm en t with the lower doses of anti- 
T N F -a  at - 2 7  h com bined with a suboptimal dose (400 ng) of 
IL-1 at — 24 h enhanced  survival rates com pared  with those 
with an ti-T N F -a  or IL-1 separately (Fig. 2A, shown for 15 fxg 
per mouse). A n ti-T N F-a  (400 jxg) adm inistered i.v. at 27 h 
before infection induced protection similar to that induced by 
800 ng of IL-1 adm inistered i.p. at - 2 4  h, and combination of 
the two trea tm ents  could not further enhance survival (Fig. 
2B).
P re trea tm en t at - 2 7  h with a low, nonprotective dose of 
an ti-T N F-a  (5 jjig i.v.) consistently tended  to reduce the 
protective effect induced by 800 ng of IL-1 i.p. at —24 h. 
A lthough the difference between the effects of IL-1 with 
an ti-T N F-a  and with IgG did not reach statistical significance, 
the addition of an ti-T N F -a  abolished the significant difference 
of IL-1 trea tm ent from the controls (Fig. 2C).
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FIG. 2. (A) Survival of neutropenic mice pretreated i.v. with 15 jjLg 
of the anti-TNF-a antibody Vlq or the same amount of control IgG at 
27 h and/or treated i.p. with 400 ng of rhIL-lß or control substance 
(heat-inactivated IL-lß) at 24 h before a lethal i.m. P. aeruginosa 
challenge. Significant differences in survival between mice treated with 
IgG plus heat-inactivated IL-lß, mice treated with IgG plus IL-1 (x_ = 
5.68 and P < 0.025), and mice treated with anti-TNF-a plus IL-1 (x2 
= 8.79 and P < 0.005; 10 mice per group) are present. (B) Survival of 
neutropenic mice pretreated i.v. with 400 pig of the anti-TNF-a 
antibody V lq or the same amount of control IgG at 27 h and/or treated 
i.p. with 800 ng of rhIL-lß or control substance (heat-inactivated 
IL-lß) at 24 h before a lethal i.m. P. aeruginosa infection. Significant 
differences in survival between mice treated with IgG plus heat- 
inactivated IL-lß, mice treated with IgG plus IL-1 (x2 =  12.09 and P 
< 0.01), mice treated with anti-TNF-a (x2 =  4.85 and P < 0.05), and 
mice treated with anti-TNF-a plus IL-1 (x2 =  8.72 and P < 0.005; 29 
to 31 mice per group) are present. (C) Survival of neutropenic mice 
pretreated i.v. with 5 fxg of the anti-TNF-a antibody Vlq or the same 
amount of control IgG at 27 h and/or treated i.p. with 800 ng of 
rhIL-lß or control substance (heat-inactivated IL-lß) at 24 h before a 
lethal i.m. P. aeruginosa infection. Although survival of mice treated 
with rhIL-lß plus anti-TNF-a is consistently lower than that of mice 
treated with rhIL-lß plus control IgG, these differences did not reach 
significance. However, no significant difference in survival between 
mice treated with anti-TNF-a plus heat-inactivated IL-lß and mice 
treated with anti-TNF-a plus IL-1 is present, whereas the difference in 
survival between mice treated with IgG plus heat-inactivated IL-lß 
and mice treated with IgG plus IL-1 is significant (x2 = 12.09 and P < 
0.001 ; 18 to 20 mice per group).
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FIG. 3. (A) Survival of neutropenic mice treated orally with 30 mg 
of WEB 2170 per kg or with vehicle (carboxymethyl cellulose [CMC]) 
at 25 li and injected i.p. with 800 ng of rhIL-lß or control substance 
(heat-inactivated IL-lß) at 24 h before a lethal i.m. P. aeruginosa 
challenge. Survival of IL-1-treated mice pretreated with WEB 2170 or 
vehicle is significantly enhanced in comparison with the survival of 
mice that received vehicle followed by heat-inactivated IL-lß ( \2 = 
7.43 and 14.88 and P < 0.01 and P < 0.0005, respectively). The survival 
of IL-1-treated mice after pretreatment with WEB 2170 does not differ 
significantly from that of vehicle-pretreated mice ( \2 = 1.44 and P >
0.2; 29 and 30 mice per group). (B) Survival of neutropenic mice 
treated orally with 30 mg of MK-886 per kg or with vehicle at 25 h and
1.p. with 800 ng of rh IL-lß or control substance (heat-inactivated 
IL-lß) at 24 li before a lethal i.m. P. aeruginosa challenge. Survival of 
IL-l-treated mice pretreated with MK-886 or vehicle is significantly 
enhanced in comparison with the survival of mice that received vehicle 
followed by heat-inactivated IL-lß (x2 = 7.72 and 13.27 and P < 0.01 
and P < 0.0005, respectively). The survival of IL-l-treated mice after 
pretreatment with MK-886 does not differ significantly from that of 
vehicle-pretreated mice (x" = 1-44 and P > 0.2; 23 mice per group).
Effect of GM-CSF compared with IL-l-induced protection 
from infection. Next, we investigated w hether G M -C SF might 
be a m edia to r  of IL-l-induced protection from infection. A 
dose range of G M -C SF expected to be physiologically relevant 
was investigated; G M -C SF was adm inistered i.p. to n eu tro ­
penic mice 24 h before a lethal i.m. challenge with P. aerugi- 
uosa. Survival was not affected by 0.5, 1, 2, 5, or 10 jxg of 
G M -C SF in com parison with survival in control mice (28 mice 
per group; results not shown).
Effect of pretreatment with inhibitors of PAF, lipooxygen- 
ase, and cyclooxygenase on IL-l-induced enhanced survival. 
To assess the role of PA F in IL -l-induced  protection, we 
adm inistered W EB 2170, a PA F recep tor antagonist, in differ­
ent oral doses (10, 30, and 150 mg/kg of body weight) 1 h 
before 800 ng o f  IL-1. Such dosage schedules, reported  to be 
effective in inhibition of PA F effects (14, 15), did not signifi­
cantly influence IL -l- induced  protection in com parison with 
p re trea tm en t with vehicle (shown for 30 mg/kg in Fig. 3A). The 
same doses of W EB 2170 per se did not affect survival in 
com parison with vehicle trea tm en t (data  not shown).
Next, we investigated the role of leukotrienes in IL -l-
induced protection from infection by adm inistration of MK- 
886 , an inhibitor of lipoxygenase translocation. M K -886 (10, 
30, or 150 mg/kg) was adm inistered orally 1 h before i.p. 
injection of 800 ng of IL-1. Such dosage schedules (reported  to 
be effective in inhibition of leukotriene effects [45]) did not 
reduce survival in comparison with p re trea tm en t of mice with 
vehicle. Suivival of mice treated  with different doses of MK- 
886 did not differ significantly from that of mice treated  with 
vehicle (shown for 30 mg/kg in Fig. 3B).
P re trea tm ent with indom ethacin, ibuprofen, or acetylsali- 
cylic acid adm inistered orally or intraperitoneally in doses 
reported  to completely inhibit cyclooxygenase effects (5, 45, 
and 220 mg/kg, respectively) (21) did not affect IL-l-induced 
enhanced  survival. Survival after adm inistration of these cy­
clooxygenase inhibitors per se did not differ from survival after 
p re trea tm en t with vehicle (20 mice per group; data  not shown).
DISCUSSION
In the present study, we investigated the potential role of 
T N F -a , G M -CSF, platelet-activating factor, and arachidonic 
acid m etabolites in IL -l- induced  enhanced  resistance to infec­
tion. These m ediators are induced by IL-1 (2, 3, 8 , 26, 29) and 
potentially increase host resistance to infection. In the exper­
iments presented  here, we found that only m urine T N F -a  gave 
protection and that adm inistration of G M -CSF, inhibitors of 
PAF, inhibitors of lipooxygenase, and inhibitors o f  cyclooxy­
genase did not influence survival rates.
Although T N F  pre trea tm en t has been shown to enhance 
resistance to bacterial, fungal, viral, and protozoal infections 
(7, 25, 31), adm inistration of hum an T N F -a  in our infection 
model in doses expected to be effective in vivo (25) did not 
mimic the protective effect of IL-1. Since many effects of 
T N F -a  have been  shown to be species specific (20), we 
assessed the effect of m urine rTN F-a. P re trea tm en t with 800 
ng of m urine T N F -a  was found to give protection  to about the 
same degree as 80 ng of rhIL-1. The difference in protection 
between hum an and m urine T N F -a  in mice could indicate that 
the protective effects are predom inantly  m ediated  via the 
m urine type II T N F  receptor, since this receptor has a much 
stronger specificity for m urine T N F -a  than does the type I 
T N F  receptor (20).
Not only m urine T N F -a  p re trea tm en t but also p re trea tm en t 
with a high dose of an ti-T N F -a  immunoglobulin was shown to 
induce a dose-rela ted  level of protection against a lethal P. 
aeruginosa challenge. This level of protection could be en ­
hanced by coadm inistration of a suboptimal dose of IL-1. A 
higher dose o f  an ti-T N F -a  (400 fjig) induced a level of p ro tec­
tion similar to that induced by 800 ng of IL-1, and combined 
trea tm en t did not further increase survival rates. This suggests 
that IL-1 and an ti-T N F -a  exert their protective effect through 
a similar pathway and that this pathway is already maximally 
affected by 400 fxg of an ti-T N F-a  or 800 ng of IL-1. Since the 
levels of protection induced by this high dose of an ti-T N F-a  
were similar when it was adm inistered at 27 or 3 h before 
infection, it is likely that the mode of action is interference with 
deleterious effects of excess T N F -a  during the lethal cytokine- 
mic phase of the infection (35, 36). In fact, in neutropenic  rats 
a protective effect of an an ti-T N F-a  M Ab against infection 
with P. aeruginosa has been shown (27). T he  small am ount of 
endotoxin contam ination  of ou r  an ti-T N F -a  prepara tion  could 
not explain its protective effect, but the serum  half-life of the 
antibody of about 24 h (7) is sufficient to obtain such an effect 
in the experimental model used. T he  way IL-1 trea tm en t could 
interfere with the lethal cytokinemic phase of infection is by 
decreased cytokine production or by downregulation of cyto-
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kine receptors resulting in reduced effects of the cytokine 
overshoot (42, 44). Studies on such IL-1 effects are currently in 
progress.
The paradox that mouse T N F -a  as well as an ti-T N F-a  given 
at - 2 4  h gives protection should probably be explained in a 
similar fashion. T N F  p re trea tm en t may enhance host defense 
mechanisms like phagocyte activation and induction of acute- 
phase proteins (31, 33, 34). It may also, like an ti-T N F-a  and 
IL-1, protect the host by interference with lethal cytokinemia 
during infection, e ither by desensitization of target cells to the 
toxic effects of cytokines, by inducing refractoriness of cyto­
kine-producing cells resulting in reduced production after 
infection, or by induction of TN F-binding proteins (9, 16, 19, 
42). A dm inistration of a low dose of an ti-TN F-a , which by 
itself did not enhance  survival, seems to diminish IL -l- induced  
protection. This result, com bined with the observation of a 
m odera te  protective effect of p re trea tm en t with rm T N F -a , 
suggests that endogenously produced T N F -a  contributes to the 
protective effect of IL-1.
G M -C SF would be a good candidate  as a m edia to r of 
IL -l-induced  protection (5). R eports  on enhancem ent of an ­
timicrobial resistance by G M -C SF in vitro are num erous (11). 
In vivo protective effects of p re trea tm en t with low doses of 
G M -C SF have been shown in experim ental models of bacterial 
as well as viral infections (10, 17), but this is not a universal 
finding (24). In addition to stimulating hematopoiesis, G M - 
CSF is able to activate m ature  phagocytes and induces several 
secondary m ediators  (11, 23, 30, 32). IL-1 might give p ro tec­
tion, via G M -C SF or directly, by activating m acrophages, since 
24 h after a single dose of G M -C SF (1 fxg) m acrophages are 
still activated (23). O ur  finding of a lack of protective effect of 
G M -C SF adm inistration argues against a role of G M -C SF as a 
m ediator of IL -l-induced  enhanced resistance, although for 
conclusive evidence additional studies with inhibitors of en d o ­
genous G M -C S F  would be necessary.
Studies showing a lack of effect of inhibitors of PA F (14) and 
leukotrienes (12) adm inistered prior to IL-1 argue against a 
role of these lipid m ediators in IL -l- induced  enhanced resis­
tance to infection.
In an extension of previous experim ents (36), inhibition of 
induction of prostaglandins and throm boxanes by IL-1 by 
p re trea tm en t with several cyclooxygenase inhibitors did not 
affect IL -l- induced  resistance to infection, providing addi­
tional evidence against a role of cyclooxygenase products.
We conclude that the protective effect of p re trea tm en t of 
neu tropenic  mice with a low dose of IL-1 in a lethal P. 
aeruginosa infection is not m ediated  by induction of GM -CSF, 
PAF, leukotrienes, or cyclooxygenase products, but that T N F a  
is likely to contribute  to IL -l- induced  protection.
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